North America Pharmaceutical CDMO for Formulations Market Size to Hit USD 18.37 Billion by 2026

North America Pharmaceutical CDMO for Formulations Market (By Dosage Form: Oral Solids, Oral Liquids, Injectables, Topicals, Inhalation Products, Transdermal And Patches, Others; By Therapeutic Area: Oncology, Cardiology, Central Nervous System, Gastroenterology, Infectious Diseases, Endocrinology (Diabetes, Hormonal Therapy); By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Others) Industry Size, Share, Growth, Trends 2025 to 2035

Report Code : 599 | Published : 11 May 2026 | Delivery : Immediate | Format : Excel | Author : Aditi Shivarkar, Aman Singh

Revenue,

USD 17.1 Bn

Forecast Year,

USD 34.92 Bn

CAGR, 2026 - 2035

7.40%

Report Coverage

North America

Download Databook

The North America pharmaceutical CDMO for formulations market size was estimated at USD 17.10 billion in 2025 and is projected to be worth around USD 34.92 billion by 2035, is expanding at a CAGR of 7.40% from 2026 to 2035. Because pharmaceutical company are increasingly outsourcing formulation and manufacturing services to reduce cost and speed up drug development.

North America Pharmaceutical CDMO for Formulations Market Statical Scope

Reports Attributes	Statistics
Market Size in 2025	USD 17.10 Billion
Market Size in 2026	USD 18.37 Billion
Market Size by 2035	USD 34.92 Billion
CAGR 2026 to 2035	7.40%
Base Year	2025
Forecast Period	2026 to 2035

A major market trend is the rising demand for biologics , specialty medicines, and complex formulations, along with stronger partnerships between pharma companies and CDMOs for efficient production and supply chains.

Advanced technologies such as continuous manufacturing, automation, nano - formulations, and modern analytical tools are improving product quality, product quality, scalability, and development efficiency across the market.

Segments	Shares (%)
Oral Solids	31%
Oral Liquids	11%
Injectables	27%
Topicals	9%
Inhalation Products	8%
Transdermal and Patches	10%
Others	4%

Oral Solids - The oral solids segment dominated the market with a share of 31% in 2025, due to high demand for tablets and capsules, cost- effective manufacturing, patient convenience, and strong outsourcing by pharmaceutical companies.
Oral Liquids - The oral liquids are rapidly growing with a market share of 11%, due to growing paediatric and geriatric demand, easier swallowing, flexible dosing, and increasing using cough and nutritional medicines.
Injectables - The injectables segment held a 27% market share in 2025 and is expected to grow at a steady rate, due to rising biologics demand, rapid drug action, increasing chronic diseases, and strong outsourcing of sterile manufacturing services.

Segments	Shares (%)
Oncology	29%
Cardiology	18%
Central Nervous System	17%
Gastroenterology	11%
Infectious Diseases	13%
Endocrinology (Diabetes, Hormonal Therapy)	12%

Oncology - The oncology segment dominated the market with a share of 29% in 2025, due to increasing cancer cases, strong biologics development, high R&D Spending, And growing demand for targeted therapies.
Cardiology - The cardiology segment held a 18% market share in 2025 and is expected to grow at a steady rate, due to rising cardiovascular diseases, increasing demand for long-term medications, and growing outsourcing of complex cardiac drug formulations.
Central Nervous System - The central nervous system are rapidly growing with a market share of 17%, due to rising neurological disorders, growing mental health treatments, and increase the development of advanced CNS drug formulations.

Segments	Shares (%)
Pharmaceutical Companies	54%
Biopharmaceutical Companies	37%
Others	9%

Pharmaceutical Companies - The pharmaceutical companies segment dominated the market with a share of 54% in 2025, due to increased outsourcing, large-scale drug production, cost reduction strategies, and raising demand for faster product development.
Biopharmaceutical Companies - The biopharmaceutical companies segment held a 37% market share in 2025 and is expected to grow at a steady rate, due to rising biologics developments, increasing outsourcing needs, complex formulations, and growing demand for the specialised manufacturing expertise.
Others - The others are rapidly growing with a market share of 9%, due to increasing research activities, small-scale outsourcing needs, and demand form academic and specialty healthcare organisations.

Top Companies in the North America Pharmaceutical CDMO for Formulations Market

Lonza
Thermo Fisher Scientific, Inc.
Recipharm AB
Laboratory Corporation of America Holdings (LabCorp)
Catalent, Inc.
WuXi AppTec, Inc.
Piramal Pharma Solutions
Siegfried Holding AG
CordenPharma International
Cambrex Corporation
Bushu Pharmaceuticals Ltd.
Nipro Corporation
EuroAPI
Hovione
Curia

Segments Covered in the Report

By Dosage Form

Oral Solids
Oral Liquids
Injectables
Topicals
Inhalation Products
Transdermal And Patches
Others

By Therapeutic Area

Oncology
Cardiology
Central Nervous System
Gastroenterology
Infectious Diseases
Endocrinology (Diabetes, Hormonal Therapy)

By End User

Pharmaceutical Companies
Biopharmaceutical Companies
Others

List of Tables & Figures

List of Tables

Table 1: North America Pharmaceutical CDMO for Formulations Market Size, by Dosage Form, 2025-2035 (USD Billion)
Table 2: North America Pharmaceutical CDMO for Formulations Market Size, by Oral Solids, 2025-2035 (USD Billion)
Table 3: North America Pharmaceutical CDMO for Formulations Market Size, by Oral Liquids, 2025-2035 (USD Billion)
Table 4: North America Pharmaceutical CDMO for Formulations Market Size, by Injectables, 2025-2035 (USD Billion)
Table 5: North America Pharmaceutical CDMO for Formulations Market Size, by Topicals, 2025-2035 (USD Billion)
Table 6: North America Pharmaceutical CDMO for Formulations Market Size, by Inhalation Products, 2025-2035 (USD Billion)
Table 7: North America Pharmaceutical CDMO for Formulations Market Size, by Transdermal & Patches, 2025-2035 (USD Billion)
Table 8: North America Pharmaceutical CDMO for Formulations Market Size, by Others (Dosage Form), 2025-2035 (USD Billion)
Table 9: North America Pharmaceutical CDMO for Formulations Market Size, by Therapeutic Area, 2025-2035 (USD Billion)
Table 10: North America Pharmaceutical CDMO for Formulations Market Size, by Oncology, 2025-2035 (USD Billion)
Table 11: North America Pharmaceutical CDMO for Formulations Market Size, by Cardiology, 2025-2035 (USD Billion)
Table 12: North America Pharmaceutical CDMO for Formulations Market Size, by Central Nervous System, 2025-2035 (USD Billion)
Table 13: North America Pharmaceutical CDMO for Formulations Market Size, by Gastroenterology, 2025-2035 (USD Billion)
Table 14: North America Pharmaceutical CDMO for Formulations Market Size, by Infectious Diseases, 2025-2035 (USD Billion)
Table 15: North America Pharmaceutical CDMO for Formulations Market Size, by Endocrinology (Diabetes, Hormonal Therapy), 2025-2035 (USD Billion)
Table 16: North America Pharmaceutical CDMO for Formulations Market Size, by End User, 2025-2035 (USD Billion)
Table 17: North America Pharmaceutical CDMO for Formulations Market Size, by Pharmaceutical Companies, 2025-2035 (USD Billion)
Table 18: North America Pharmaceutical CDMO for Formulations Market Size, by Biopharmaceutical Companies, 2025-2035 (USD Billion)
Table 19: North America Pharmaceutical CDMO for Formulations Market Size, by Others (End User), 2025-2035 (USD Billion)
Table 20: U.S. Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 21: Canada Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 22: Mexico Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 23: North America Pharmaceutical CDMO for Formulations Market Share, by Dosage Form, 2025 (%)
Table 24: North America Pharmaceutical CDMO for Formulations Market Share, by Therapeutic Area, 2025 (%)
Table 25: North America Pharmaceutical CDMO for Formulations Market Share, by End User, 2025 (%)

List of Figures

Figure 1: North America Pharmaceutical CDMO for Formulations Market Share, by Dosage Form, 2025 (%)
Figure 2: North America Pharmaceutical CDMO for Formulations Market Share, by Therapeutic Area, 2025 (%)
Figure 3: North America Pharmaceutical CDMO for Formulations Market Share, by End User, 2025 (%)
Figure 4: North America Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 5: North America Oral Solids Market Forecast, 2025-2035 (USD Billion)
Figure 6: North America Oral Liquids Market Forecast, 2025-2035 (USD Billion)
Figure 7: North America Injectables Market Forecast, 2025-2035 (USD Billion)
Figure 8: North America Topicals Market Forecast, 2025-2035 (USD Billion)
Figure 9: North America Inhalation Products Market Forecast, 2025-2035 (USD Billion)
Figure 10: North America Transdermal & Patches Market Forecast, 2025-2035 (USD Billion)
Figure 11: North America Oncology Market Forecast, 2025-2035 (USD Billion)
Figure 12: North America Cardiology Market Forecast, 2025-2035 (USD Billion)
Figure 13: North America Central Nervous System Market Forecast, 2025-2035 (USD Billion)
Figure 14: North America Gastroenterology Market Forecast, 2025-2035 (USD Billion)
Figure 15: North America Infectious Diseases Market Forecast, 2025-2035 (USD Billion)
Figure 16: North America Endocrinology Market Forecast, 2025-2035 (USD Billion)
Figure 17: North America Pharmaceutical Companies Segment Forecast, 2025-2035 (USD Billion)
Figure 18: North America Biopharmaceutical Companies Segment Forecast, 2025-2035 (USD Billion)
Figure 19: U.S. Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 20: Canada Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 21: Mexico Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)

Research Methodology

Related Databooks

March 2026